

MAJOR REVIEW

Scleritis

Narciss Okhravi, PhD, FRCOphth,¹ Bola Odufuwa, FRCOphth,¹ Peter McCluskey, MD, FRCS,² and Susan Lightman, PhD, FRCOphth¹

¹Department of Clinical Ophthalmology, Institute of Ophthalmology, Moorfields Eye Hospital, City Road, London EC1V 2PD, United Kingdom; and ²Department of Ophthalmology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, 2050, Australia

Abstract. Scleritis is typically a severe painful inflammatory process centered in the sclera that may involve the cornea, adjacent episclera, and underlying uvea; it poses a significant threat to vision. Careful clinical history taking, detailed ocular examination, appropriate investigation for ocular disease with or without underlying systemic disease, and timely intervention with the use of immunosuppressant drugs when necessary, has improved the long-term outcome for patients with this disease. (*Surv Ophthalmol* 50:351–363, 2005. © 2005 Elsevier Inc. All rights reserved.)

Key words. autoimmune • episcleritis • infectious • masquerade • necrotizing • nodular • scleritis • scleromalacia

I. Introduction

Scleritis is defined as inflammation of the sclera, and it has a characteristic clinical picture. It is typically a severe painful inflammatory process centered in the sclera that may involve the cornea, adjacent episclera, and underlying uvea; it poses a significant threat to vision. Up to 50% of patients with scleritis have evidence of an underlying systemic disease. Scleritis is usually suspected from the clinical history, and it is confirmed by its characteristic clinical signs. When the posterior sclera is involved, clinical signs may be less obvious and ultrasonography or other imaging studies may be necessary to confirm the diagnosis.

A. OCULAR ANATOMY

In order to understand the pathophysiology of this condition, a review of ocular surface anatomy is

required. The sclera is an incomplete shell comprising approximately 90% of the outer coat of the eye; it begins at the limbus and terminates at the optic canal. The sclera is composed of extracellular matrix—collagen, elastin, proteoglycans, the bundles of which run in whorls and loops. The innermost part of the sclera is the lamina fusca, which has many grooves caused by the passage of ciliary vessels and nerves. Anteriorly, the sclera is continuous with the cornea at the corneoscleral junction, and lying just posterior to this, within the sclera, is the canal of Schlemm. Posterior to the canal is the scleral spur, which is triangular with its apex pointing anteriorly and inward and attaching to the ciliary body. The posterior pole of the sclera is weakened and has a sieve-like appearance (lamina cribrosa) where it is perforated by the axons of the optic nerve. Here, the sclera is fused with the dura mater and arachnoid sheaths of the optic nerve, hence explaining the optic

nerve swelling seen in 43% of eyes with posterior scleritis.¹⁷ The sclera has a rich sensory innervation from the ciliary nerves, which pierce the sclera around the optic nerve. Many short posterior ciliary nerves supply the posterior portions and two long posterior ciliary nerves supply the anterior region. Because the extraocular muscles are inserted into the sclera, the dull ache of scleral inflammation is made worse by ocular movement.¹¹⁶

In order to reliably differentiate episcleritis and scleritis, an understanding of the anatomy of the vascular plexuses contained within the conjunctiva, episclera, and sclera is essential. There is a vascular plexus of vessels within the conjunctiva and two vascular layers within the episclera, superficial and deep. The sclera itself is avascular, and, therefore, highly dependent on the vascular coats on either side. Anteriorly, the episclera has a rich blood supply from the anterior ciliary arteries, which form a rich plexus deep to the conjunctiva. These vessels form extensive collateral arterial anastomoses with the posterior ciliary arteries at the root of the iris and are normally inconspicuous but become visibly congested in the presence of inflammation.¹¹⁶ The anterior vascular system is readily visible with the slit-lamp and can be imaged by fluorescein angiography.¹²⁷ The superficial episcleral capillary plexus is a radially arranged series of vessels, which anastomose at the limbus with the conjunctival vessels and with the deep plexus. The deep episcleral capillary network is closely applied to the sclera. Posteriorly, four vortex veins drain the choroidal circulation, pierce the sclera posterior to the equator, and join the ophthalmic vein.¹¹⁶

B. DIFFERENCE BETWEEN SCLERITIS AND EPISCLERITIS

Scleritis is often confused with episcleritis, which is inflammation confined to the superficial episcleral tissue and does not involve the deep episcleral tissue that overlies the sclera. Episcleritis is a mild non-vision-threatening form of ocular inflammation that is usually idiopathic in nature and is not usually associated with involvement of other ocular structures although adjacent corneal involvement can be seen and the intraocular pressure may be raised. The clinical differentiation of episcleritis and scleritis involves a detailed history and a careful ocular examination to determine which layers of the wall of the eye are involved by inflammation. Differentiation is important at presentation as management, prognosis, and complications are very different for these two diseases and long term studies have shown that very few patients progress from one to develop the other.^{107,121}

To sort out the clinical signs it is essential to understand the anatomy of the episclera and sclera, the

vascular plexuses contained therein, and to appreciate the examination techniques that allow this determination. The key clinical observations in patients with scleral inflammation involve determining the relationship of the vascular plexuses to each other and the site of maximal vascular involvement, best seen with red-free light on slit-lamp biomicroscopy. In episcleritis, the conjunctival and superficial episcleral vascular plexuses are displaced outward from the sclera and the underlying deep episcleral plexus is uninvolved and flat against normal-thickness scleral tissue. In scleritis all vascular layers may be involved but the maximal involvement is in the deep episcleral plexus, which is displaced outward by edematous swollen sclera. This displacement of the deep episcleral vessels is seen only in patients with scleritis.

In episcleritis the patient's main complaint is often redness, which may also be associated with a feeling of grittiness. This is in contrast to scleral inflammation, where pain is much more prominent along with globe tenderness and redness that may involve the whole eye or just a small localized area. The vascular engorgement of the deep episcleral plexus in scleritis has a characteristic bluish-violet hue, which is not present in patients with episcleritis, in which case the engorgement of the superficial episcleral plexus has a distinct red hue. Episcleritis may be associated with nodules and may overlie an area of anterior scleritis. Examination in natural daylight can be extremely useful allowing the detection of these subtle color differences that are often not appreciable using the slit-lamp. Additionally, slit-lamp examination with red-free light and diffuse illumination accentuates visibility of blood vessels and areas of capillary nonperfusion. In addition, the conjunctival and superficial vessels can be blanched with 2.5–10% phenylephrine or 1:1,000 epinephrine while the deep vessels are hardly affected.

II. Immunopathology

Most eyes with scleritis do not come to biopsy or to enucleation. In one study of enucleated eyes, eyes with necrotizing scleritis showed vasculitis with fibrinoid necrosis and neutrophil invasion of the vessel wall in 75%, and vascular immunodeposits were found in 93% in the scleral tissue. In addition, there was a significant increase in the number of inflammatory cells, including T cells of all types and macrophages. HLA-DR expression was dramatically increased.²⁹ Studies of deep episcleral biopsies from patients with nodular non-necrotizing scleritis did not show the same findings and vasculitis was not prominent.⁹ T cells and macrophages were the major inflammatory cells seen infiltrating the deep episcleral tissue with clusters of B cells in perivascular areas. Increased

HLA-DR expression was seen as well as increased IL-2 receptor expression on the T cells, suggesting an active cell-mediated immune response.⁸ Others found neutrophils and granulomatous inflammation in enucleated eyes with necrotizing disease.⁹⁹ Antibody deposition was not seen nor was complement found, suggesting that T cells are the effector cell in scleritis rather than immune complex deposition. Plasma cells may be involved through production of matrix metalloproteinases, which can cause destruction and remodeling,²³ and TNF alpha, a pro-inflammatory cytokine.²⁴

III. Classification of Scleral Inflammation

The classification system devised by Watson is accepted as the most clinically useful. It is anatomically based and is detailed in Table 1. Episcleritis is recognizable in the anterior episclera as a diffuse process or less commonly as a nodular form of episcleral inflammation. Posterior episcleritis occurs and has been documented pathologically but is not recognizable as a clinical entity.

Scleritis may involve the anterior sclera, posterior sclera or both.¹⁰⁷ Anterior scleritis is the most common pattern of disease, and it may be diffuse, nodular, or necrotizing in type. Very rarely a necrotizing form of anterior scleritis occurs in the absence of pain and other clinical signs of inflammation in patients with longstanding rheumatoid arthritis and is termed scleromalacia perforans.

Posterior scleritis is defined as involvement of the sclera posterior to the insertion of the rectus muscles and may be difficult to recognize in the absence of good imaging as there may be little in the way of physical signs. Modern B-scan ultrasonography and high-definition orbital magnetic resonance imaging are used to detect posterior scleritis and both

diffuse and nodular forms can be identified. Necrotizing posterior scleritis has been reported on histopathological examination of enucleated eyes but cannot be recognized clinically at this time.

IV. Presentation of Scleritis

Patients with scleritis may present in one of two ways—they may already be known to have an underlying related disorder, such as rheumatoid arthritis, or the scleritis may present de novo in the absence of any known underlying systemic disease.¹⁰⁷ The characteristic feature of scleritis is the severe pain that may involve the eye and orbit and radiates to involve the ear, scalp, face, and jaw. Scleritic pain is typically dull and boring in nature, exacerbated by eye movement, is worse at night often interfering with sleep, and characteristically awakens the patient from sleep early in the morning. Scleritis has a subacute onset and the intensity of the pain may increase over several weeks. The pain is usually severe in nature and often resistant to mild analgesics. The pain can be so severe that it prevents the patient from working and performing their normal activities and of such severity that the patient is investigated and/or treated for other causes of severe headache, such as migraine, giant cell arteritis, tic doloureux, cerebral aneurysm, and tumor. Patients may also be thought to have depression or other psychological disturbance. Some patients with scleritis, however, have no pain or may have little pain because of a partial effect from the use of non-steroidal anti-inflammatory drugs.

The patient with anterior scleritis usually notices redness and tenderness of the globe. There may be photophobia and lacrimation. Patients with posterior scleritis may present with reduced vision with or without pain. Unilateral or bilateral inflammation can occur. Patients may have an underlying systemic disorder but not all do and many remain healthy. Although most scleritis is immune-mediated, it can also be triggered by infection, ocular surgery, malignancy, or drugs. There are different types of scleritis that have differing threats to vision, and, therefore, careful clinical examination is paramount.

V. Signs

The signs of scleritis depend on the location of the scleritis and its severity.¹⁰⁷ The hallmark signs of scleral inflammation are the development of scleral edema and dilatation or closure of the deep episcleral vascular plexus. Each pattern of scleritis has physical signs that allow its recognition and are described below.

TABLE 1

Classification of Scleral Inflammation

| Type | Subtypes |
|---------------------|---|
| Episcleritis | Diffuse Nodular |
| Anterior Scleritis | Diffuse Nodular Necrotizing With inflammation Without inflammation Scleromalacia perforans |
| Posterior Scleritis | Diffuse Nodular Necrotizing (at least on histopathology) |




Fig. 1. Diffuse anterior scleritis. Note dilated blood vessels persist despite instillation of phenylephrine drops (pupil is dilated). The reflex on the cornea is as a result of flash photography and does not represent keratitis.

A. ANTERIOR SCLERITIS

Anterior scleritis is the most common form of scleral inflammation and is characterized by diffuse involvement of the anterior sclera by edema and dilation of the deep episcleral vascular plexus (Fig. 1). It can be localized to a patch of the sclera or may involve the entire anterior sclera. The patient may be photophobic and the globe is usually tender to touch, which may be extremely so. Signs of corneal infiltrates, thinning, or stromal keratitis may be present with corneal ulceration much less common than with necrotizing disease.¹⁰⁵ The underlying trabecular meshwork can be involved (trabeculitis) with resultant raised intraocular pressure also occurring due to the raised episcleral venous pressure.¹³⁰ In isolated anterior scleritis, no posterior segment signs are seen and ultrasound shows no thickening of the posterior coats of the eye.

Nodular anterior scleritis is characterized by a more localized area of scleral edema such that distinct nodules result. They may be single or multiple and can become quite prominent and tender to palpation (Fig. 2). There is no evidence of capillary



Fig. 2. Nodular scleritis. Note large nodule and rest of sclera is uninvolved.




Fig. 3. Necrotizing anterior scleritis. Note large area where sclera is ulcerated and overlying conjunctiva and episclera are missing.

closure or non-perfusion and no evidence of scleral necrosis.

B. NECROTIZING ANTERIOR SCLERITIS

Necrotizing anterior scleritis is the most severe form of scleritis and is a serious threat to vision and the integrity of the eye.¹²¹ There is usually severe pain and extreme scleral tenderness. The scleral involvement is characterized by severe vasculitis and closure of the episcleral vascular bed such that there are visible areas of capillary non-perfusion on clinical examination, and infarction and necrosis of the involved sclera (Fig. 3). Necrosis of the sclera can be subtle or profound, localized, or generalized, and progress rapidly to expose the choroid. There is commonly spread of inflammation that involves the cornea, ciliary body, and trabecular meshwork, resulting in keratitis, anterior uveitis, and elevated intraocular pressure, which may lead to staphyloma formation, although this latter finding may be witnessed without coexistent raised intraocular pressure.¹⁰⁷ Although the necrosis may be seen anteriorly its exact extent may be difficult to visualize or detect using ultrasound as this only detects scleral thickening.

C. SCLEROMALACIA PERFORANS

Scleromalacia perforans is now a very rare form of necrotizing anterior scleritis that is the result of an obliterative arteritis involving the deep episcleral vascular plexus.^{70,90,107} It does not produce the acute clinical signs of necrotizing scleritis described above but is asymptomatic or presents with blurred vision from high astigmatism due to scleral thinning leading to loss of scleral rigidity. The sclera is parchment white, avascular, and thin. There may be exposure of the choroid and staphyloma formation if the




Fig. 4. B-scan ultrasound demonstrating posterior scleritis. Note localized thickened area indicating area of posterior scleral swelling.

intraocular pressure is elevated. There may be sequestra of infarcted sclera surrounded by areas of thinning scleral tissue. There is no corneal involvement except for limited peripheral corneal thinning.

D. POSTERIOR SCLERITIS

Diffuse and nodular forms of posterior scleritis can be delineated from the clinical signs or with the use of imaging studies such as B-scan ultrasonography and magnetic resonance imaging (Fig. 4). The clinical presentation of posterior scleritis depends on the location, extent, and severity of involvement of the posterior sclera.⁷⁷ Posterior scleritis may occur in association with anterior scleritis or may be isolated. In either case the pain is typical except in the rare cases of scleromalacia perforans when the necrosis is painless. In patients with associated anterior scleritis, the eye is red. When it occurs in isolation, the eye may be white, but sometimes inflamed posterior sclera can be visualized coming from behind the eye in the extremes of gaze. Ultrasound remains the key to diagnosis with which the thickened posterior coat of the eye (usually greater than 2 mm) can be identified. The posterior segment may appear normal or there can be a variety of signs, such as chorioretinal granulomas, serous retinal detachment, and optic nerve swelling with or without cotton-wool spots.⁴ Large serous retinal detachments can be associated with shallowing of the anterior chamber, and secondary angle-closure glaucoma from ciliary body rotation secondary to uveal effusion.⁹⁶

E. UVEITIS IN EYES WITH SCLERITIS

All types of scleritis can be associated with uveitis which may be mild or severe.¹⁰¹ Anterior uveitis occurs in up to 40% of eyes with scleritis¹⁰¹ and is more common with more severe scleritis, most

often seen in association with necrotizing disease.¹⁰⁷ It is important to be sure that it does not signify an associated endophthalmitis when seen with scleral necrosis.⁸⁹

VI. Demographic Data

Patients with scleritis are predominantly middle-aged and Caucasian with a mean age at onset of 49 years.⁷⁷ Female patients comprise 71% of all patients with scleritis⁴⁵ and 65% of patients with posterior scleritis.⁷⁷ In 30% of patients, posterior scleritis occurred before the age of 40 years. Interestingly, in a small series of patients from the West Indies a preponderance of male patients was seen with posterior scleritis, who also tend to be much younger (mean age 19 years) at presentation.¹⁷ Patients with posterior scleritis greater than the age of 50 years have been shown to have a greater risk of having an associated systemic disease, associated visual loss, and were more likely to require systemic immunosuppressive agents to control their disease.⁷⁷

VII. Classification by Etiology

The incidence of systemic disease in patients with scleritis is reported as 39–50%.^{45,77,104} There is no known HLA association.⁴⁹ It is useful to note that the association of posterior scleritis with anterior scleritis is much more likely to occur in a patient in whom there is an underlying systemic disease.⁷⁷

A. AUTOIMMUNE SYSTEMIC ASSOCIATIONS

A large number of connective-tissue disorders are associated with scleral disease but the most common is rheumatoid arthritis. Wegener granulomatosis is the most common vasculitis associated with scleritis. Other systemic diseases associated less commonly include relapsing polychondritis, inflammatory bowel disease, systemic lupus erythematosus, and polyarteritis nodosa. A large number of these systemic associations are diagnosed at the outset either because of known preexisting disease or following careful history taking and clinical examination.³⁸ Equally, as scleritis can be the presenting feature of systemic disease it is important to exclude multi-system disease at presentation, in which case control of the systemic disease is of great importance and has the beneficial effect of also controlling the ocular inflammation.^{30,38} The importance of an occult systemic autoimmune disease should not be underestimated in patients with scleritis. The spectrum of systemic investigations varies among clinicians and reflects the reported rates of associations with systemic disease. The most common systemic associations of scleritis are detailed in Table 2. Other less

TABLE 2
The Most Common Systemic Associations of Scleritis

| Disease | Key Points | Key Scleritis References |
|------------------------------|---|--------------------------|
| Rheumatoid arthritis (RA) | Features: symmetrical arthritis including hands, skin nodules, anaemia, pericarditis, fibrosing alveolitis, peripheral neuropathy Frequency: 17–33% of all patients with scleritis have RA; 0.2–6.3% of patients with RA have scleritis Helpful investigations: Rheumatoid factor positive in 60–80% of RA patients; Joint X-rays with osteopenia and erosions | 48,60,78,105 |
| Wegener's granulomatosis | Features: Epistaxis, sinusitis, haemoptysis. Ocular involvement in 50%; May involve orbit but necrotizing scleritis in 79% with peripheral ulcerative keratitis (50%) Helpful investigations: Serum c-ANCA is highly specific; Tissue biopsy shows vasculitis and necrotizing granuloma | 3,29,52,68,79,103 |
| Relapsing polychondritis | Features: Pain or swelling of ear pinnae, tracheal inflammation (in 25% with hoarse voice, cough, stridor, expiratory wheeze), collapsed nasal bridge, hearing loss, cardiac valve dysfunction, polyarthritis Helpful investigations: Raised ESR, 30% of patients have co-existing autoimmune disease, biopsy of auricular cartilage | 68,91 |
| Systemic lupus erythematosus | Features: Malar rash, skin photosensitivity, peripheral arthritis, pleuritis, pericarditis, seizures Helpful investigations: ANA positive or extractable nuclear antigen (Ro) positive; high Anti-ds DNA titre (present in 30–50%), proteinuria or casts, anaemia, leucopenia or thrombocytopenia | 60,68 |
| Polyarteritis nodosa | Features: Scleritis, ulcerative keratitis, uveitis, retinal vasculitis, pseudotumour, myalgia, weight loss, fever, arthralgia, purpura, livedo reticularis, neuropathy, hypertension, nephropathy Helpful investigations: Multiple aneurysms of either the mesenteric, hepatic, or renal systems on angiography; Muscle or sural nerve biopsy may be definitive | 60,68 |

common associations with a range of other conditions have also been reported, including juvenile rheumatoid arthritis,¹ systemic vasculitis,^{1,6,36} Vogt-Koyanagi-Harada disease,^{1,57,126} sarcoidosis,^{39,99} ankylosing spondylitis,⁵³ lymphoma,^{25,42,77} temporal arteritis,^{1,129} carcinoma of the lung,¹³³ Takayasu disease,⁴⁷ and Cogan syndrome.¹¹¹

B. INFECTIOUS CAUSES OF SCLERITIS

Infectious scleritis can be viral, bacterial, fungal, and parasitic. It is uncommon particularly in the absence of infectious keratitis. The mechanism of inflammation in many infections is thought to be partly or wholly immune mediated. Many organisms have been reported as possible causes of scleritis and these are detailed in Table 3. Infections occur in tissue compromised by disease or trauma—both iatrogenic and accidental.

In a large series of 97 patients with scleritis over a 12-year period, 7.5% had an infectious disease and the most common infection was herpes zoster ophthalmicus.⁷⁷ Pyogenic infections of the sclera are often difficult to manage and eradicate because of the poor antimicrobial penetration into the avascular necrotic sclera, but improved success has been

achieved with surgical intervention in addition to antimicrobial therapy,^{7,98} or a combination of parenteral antimicrobials.⁴⁰

A common risk factor for infectious scleritis is a history of pterygium surgery with adjunctive mitomycin C administration or beta irradiation.^{80–82} Late scleral radionecrosis has been found to occur in 4.5% of cases where beta irradiation has been used post pterygium surgery to prevent recurrence.⁶⁹ Both mitomycin C and beta irradiation have been associated with calcific plaque formation and scleral necrosis, which may occur several months to years after surgery. This may lead to defects in the overlying conjunctiva, which allows access to pathogens. Once the sclera is invaded, the infection is extremely difficult to eradicate. *Pseudomonas aeruginosa* is the most common pathogen reported.^{40,81}

Fungal scleritis may remain undiagnosed for months and a scleral biopsy is recommended in cases of progressive scleritis where infection is suspected. Bernauer et al have reported three cases of *Aspergillus* scleritis in which a combination of surgical and medical intervention was needed both for establishing the diagnosis and for successful management.⁷ A similar outcome was reported following a case of *Scedosporium*

TABLE 3
Infectious Causes of Scleritis

| Type of Organism | Specific Organism / Disease | Key Points | References |
|------------------|-------------------------------|--|-----------------------|
| Bacteria | TB | Now rare | 12,85,95,119 |
| | <i>Mycobacterium chelonae</i> | Two cases post retinal detachment surgery | 73,97 |
| | Leprosy | Incidence as high as 5% | 16,22,93 |
| | Syphilis | Most common bacterial cause accounting for 2% of cases | 19,128 |
| | Haemophilus influenzae | Nodular abscesses | 118 |
| | Pseudomonas aeruginosa | Poor prognosis | 40,81,84,97,106 |
| | Staphylococcus spp | Following surgery or beta-irradiation | 69,80–82 |
| | Streptococcus spp | Following beta irradiation and streptococcal pharyngitis | 37 |
| | Borrelia | Lyme disease | 11,58 |
| | Corynebacterium | Following trabeculectomy | 18 |
| Fungi | Serratia | Post chemotherapy | 43 |
| | Nocardia | Usually associated with trauma | 14,21,56,117 |
| | Aspergillus | Following trauma or surgery | 100 |
| | Viruses | Ebstein Barr | Necrotizing scleritis |
| Amoeba | Coxsackie B5 | Prolonged systemic upset | 34 |
| | Varicella zoster | 8% incidence of scleritis in patients with HZO | 5,67,74,86,125,131 |
| Parasite | Acanthamoeba | Associated with keratitis | 26,33,44,65 |
| | Toxoplasma | Associated with retinochoroiditis | 108,114 |

The two most common infective causes are varicella zoster and Treponemal infection.

prolificans corneoscleritis.⁵⁹ However, despite this approach the eye may still be lost to recurrent infection and intractable pain.⁴⁶ A case report of *Sporothrix schenckii* scleritis following trauma with a wood chip failed to respond to topical miconazole and topical amphotericin as well as intravenous amphotericin but had a good response to saturated solution of potassium iodide 10–24 drops orally three times a day for 10 days.¹⁵

C. MASQUERADE

Intraocular tumors such as melanomas may mimic posterior scleritis but can also be associated with it. Rarely conjunctival tumors and lymphoma can mimic scleritis and secondary malignant deposits can cause severe scleral inflammation.^{10,25,42,55,66,71,83,92,132–134} Dorey et al described two patients in whom the initial presentation of lymphoma was misdiagnosed as scleritis.²⁵ The symptoms and signs did not respond to non-steroidal anti-inflammatory drugs or to steroid treatment and further opinion was sought. Lymphoma is an important diagnosis to exclude in this circumstance. Biopsy should be considered when the pain is atypical for scleritis and the mass is salmon pink, elevated, and solid. Patients with orbital lymphoma need referral for formal staging of their disease before radiotherapy. Posterior scleritis may present as a mass lesion and some of these eyes have been enucleated erroneously.²⁸ The presence of high internal reflectivity and a retrobulbar echo-lucent area which represents oedema in the tenons capsule

on B scan should alert the examiner to the probability of posterior scleritis.^{13,28}

D. SURGICALLY INDUCED SCLERITIS

Surgically induced necrotizing scleritis (SINS) can occur after a variety of procedures, most commonly after cataract surgery particularly when a limbal incision is used with an extracapsular approach.⁸⁸ Interestingly of the patients who develop SINS, 75% of patients have undergone two or more surgical procedures prior to onset of the disease.⁸⁸ Mean time to presentation from surgery has been reported as 9 months⁹² with a range from 2 weeks to 6 months reported by others.¹⁰² Patients who have SINS need careful systemic investigation as up to 90% of patients in one study were later diagnosed with autoimmune vasculitic disease which required immunosuppression therapy.¹⁰²

Surgically induced diffuse scleritis (SIDS) is less well recognized, Scott reported 21 cases, representing 3.1% of patients who had had planned extracapsular cataract surgery with intraocular lens implantation.¹⁰⁹ Scleritis was diagnosed clinically on the basis of pain—usually sufficient to prevent or wake patient from sleep; red eye with violaceous hue adjacent to the operative wound with associated photophobia and blurred vision. They found the mean age of patients with SIDS to be significantly younger than the mean of all cataract patients. Treatment was aimed at relief of pain and control of inflammation. Local steroid treatment was ineffective and most of

the patients responded to systemic non-steroidal anti-inflammatory drugs.

E. OTHER CAUSES OF SCLERITIS

Trauma, in some cases self-inflicted, has been reported as a cause of nodular scleritis.^{54,123} Rare associated systemic diseases such as congenital erythropoietic porphyria and graft-versus-host disease following allogeneic bone marrow transplantation have also been reported.^{54,123} Drug-induced causes include scleritis following pamidronate disodium.³¹ Thurairajan et al reported a patient who suffered of polyarthopathy orbital myositis and posterior scleritis 10 days after receiving Fluvirin. Fluvirin is an inactivated influenza vaccine consisting of purified haemagglutinin and neuraminidase surface antigen in aqueous suspension.¹²⁰

VIII. Investigation of Patients With Scleritis

Blood tests for diagnosis of inflammation and systemic disease are commonly used in the investigation of these patients. In any acute presentation it is important to obtain an assessment of the patients' blood pressure, renal function (including urine analysis) and the acute phase response (normochromic normocytic anaemia, raised neutrophils platelets, Erythrocyte sedimentation rate, C-reactive protein and plasma viscosity, reduced serum albumin) in order to get an idea of the degree of systemic involvement and aid the formulation of the immediate management plan. These along with evaluation of full blood count, urea, creatinine and electrolytes, rheumatoid factor, anti-nuclear antibodies, anticytoplasmic antibodies, form the core investigations. Additional tests are requested as determined by the history and clinical examination.

Ultrasonography, fluorescein angiography or other imaging studies may be required in some patients with scleritis to confirm the diagnosis. The following ultrasonographic changes can all be seen in posterior scleritis: scleral and choroidal thickening, scleral nodules, fluid in Tenons capsule, optic disk swelling, distended optic nerve sheath, and retinal detachment.

IX. Management of Patients With Scleritis

Patients with scleritis need to have the type and extent of their disease diagnosed, the complications present detected and any underlying systemic or local cause defined. The aim of treatment is to remove or treat the cause where possible but in the majority is to control the inflammatory process to relieve the pain and thereby reduce the damage to the eye.⁷⁵

A. MEDICAL THERAPY

Patients with posterior or necrotizing scleritis need much more intensive and urgent therapy than those presenting with anterior non-necrotizing disease. Any scleritis that is associated with a systemic disease also usually requires more aggressive immunosuppressive therapy.⁷⁷

1. Cyclo-oxygenase Inhibitors (Cox Inhibitors)

Non-necrotizing scleritis often readily responds to systemic non-steroidal anti-inflammatory drugs.⁴⁵ Both non-selective cox inhibitors (e.g., flurbiprofen, indomethacin, and to a lesser extent ibuprofen) and the more selective cox-2 inhibitors have been used successfully to treat this condition, although to date scant data have been published regarding the use of the selective cox-2 inhibitors in the treatment of scleritis. Gastrointestinal side effects are prominent and patients should be warned of the possibility of gastric irritation and bleeding especially with the non-selective cox inhibitors. Photosensitivity skin rashes, renal and hepatic toxicity, and drug interactions are all important considerations.

2. Corticosteroids

Corticosteroids are usually reserved for patients who do not respond to cox-inhibitors or those with posterior or necrotizing disease.^{45,77,129} Both systemic administration and orbital floor and subconjunctival injections have been successful although local steroid injections are less commonly used.¹³⁵ Systemic corticosteroids may be administered orally or intravenously at high doses to induce disease remission. A starting dose of 1 mg/kg/day is standard with weekly reduction by 20–25 mg/week until a dose of 40 mg/day is reached. After this dose is reached, the rate of reduction is individualized, according to the clinical findings and patients' response, but is in the order of 5 mg/week until cessation or an acceptable maintenance dose is reached.^{77,129} Intravenous methylprednisolone is primarily used when a rapid control of the inflammatory response is required, for example, threatened scleral or corneal perforation in necrotizing scleritis.⁷⁶

All patients should be warned of steroid-induced side effects. These are dependant on the dose, frequency, route of administration, and duration of treatment and are more frequently seen in the elderly, diabetics, hypoalbuminaemic states, psychiatric patients, and in pregnancy. They should be used with caution in patients with gastrointestinal disease or bleeding disorders as should non-steroidal drugs.⁷² Using the lowest possible dose for the shortest possible time has the best chance of minimizing side effects and with combination therapy; it is no

longer necessary or acceptable for patients to remain on high doses of corticosteroids. Patients who relapse at doses of prednisolone >7.5–10 mg per day should be considered for adjunctive immunosuppressive therapy with a second-line agent that includes cyclosporin,^{35,124} mycophenolate,^{63,110} methotrexate,¹¹² and anti-TNF blockers.¹¹⁵ Patients with Wegener’s granulomatosis may require cyclophosphamide⁶¹ or mycophenolate,⁶² and chlorambucil is rarely used today. These patients should be referred to a specialist scleritis clinic for further management.

B. COMPLICATIONS

Scleritis has a wide range of possible complications and these depend on the location of the inflammation as well as its severity and duration (Table 4).

C. SURGERY

There are several indications for surgical intervention in patients with scleritis, but any surgical intervention is uncommon. Rarely, patients require a formal biopsy of the episclera and superficial sclera to exclude a neoplastic or infective cause for their scleritis. Also, emergency or elective tissue grafting is rarely required for tectonic globe support or to repair a perforation. Patients may also develop cataract or glaucoma that requires surgical treatment. Cataract may be secondary to intraocular inflammation and/or steroid use either topically or systemically. Raised intraocular pressure can occur with an associated trabeculitis, shallowing of the anterior chamber, or as a steroid response. Glaucoma is uncommon but develops when permanent damage to the trabecular meshwork has occurred even though the scleritis is quiescent.

1. Episcleral and Scleral Diagnostic Biopsy

In most patients with scleritis, it is clinically apparent that the patient has endogenous scleral inflammation. Patients who present with atypical clinical features such as conjunctival erosions or irregularity, a corneal perforation without severe corneal involvement, a poor response to appropriate anti-inflammatory therapy or a past history of ocular surface or periocular actinic neoplasia may have carcinomatous involvement of the episclera and sclera that masquerades as inflammatory scleritis.⁷¹ Episcleral biopsy is necessary to make the diagnosis when there is clinical doubt but this is rare. Lymphoma has also been reported presenting with episcleral masses mimicking scleritis.²⁵

Other patients including those with a past history of ocular surgery, such as pterygium surgery or retinal detachment surgery, ocular radiotherapy, or topical antimetabolite therapy to the globe, may develop infective scleritis. The presentation may be long delayed after the original treatment and there may be minimal signs suggesting an infective cause. When an infectious agent is considered likely, biopsy is essential to confirm the diagnosis and infective agent.^{41,87} Small corneal perforations may be treated with a bandage lens or glued initially¹¹³ while the inflammatory process is brought under control with high-dose corticosteroids and other agents when necessary. Elective surgery can then be performed at a time when the scleritis is quiescent.

2. Tectonic Grafting

Tissue replacement in patients with scleritis may rarely be necessary acutely when there is either corneal or scleral perforation. Management in such patients must be individualized as there is a wide range

TABLE 4
Complications of Scleritis

| Complications | Comments |
|----------------------------------|--|
| Scleral thinning | Can be severe following necrotizing disease |
| Corneal thinning and perforation | Peripheral corneal perforation is a particular feature of Wegener granulomatosis |
| Glaucoma | Central perforation more likely to be due to dry eyes associated with rheumatoid arthritis Open angle secondary to trabeculitis or raised episcleral venous pressure Narrow angle secondary to massive serous retinal detachment |
| Hypotony | Secondary to posterior synechiae leading to iris bombe |
| Uveitis | Secondary to serous or rhegmatogenous retinal detachment |
| Cataract | Uncommon—usually mild and anterior |
| Posterior segment | More common in severe and necrotizing scleritis long-term systemic steroid treatment Serous retinal detachment (localized or total retinal detachment) Choroidal folds and optic nerve involvement |
| Anterior segment ischemia | Rare—can follow 360-degree severe necrotizing anterior scleritis |
| Phthisis | Following severe scleritis |

of clinical presentations. Most frequently the patient presents with florid, uncontrolled necrotizing anterior scleritis and keratitis with either a corneal or scleral perforation. Corneal perforations are dealt with on their merits. In most patients it is possible to use conservative therapy with contact lenses and tissue adhesive^{64,87} until the scleritis is controlled with aggressive immunosuppressive therapy. The cornea can then be repaired definitively. In some patients lamellar or perforating keratoplasty is necessary in an inflamed eye. Such grafts will only survive if the scleritis is controlled with medical therapy.¹²² Scleral perforations are less common and similar principles of management are used. Lamellar corneal grafts are the easiest tissue to graft but are the most likely to be damaged by severe scleral inflammation. Donor sclera is more difficult to use but extremely robust. A variety of other tissues, such as fascia lata, dura, and pericardium, has been used for tectonic scleral support.^{27,50} Occasionally patients may develop late-onset scleral thinning or staphyloma formation that requires scleral grafting to deal with high-grade astigmatism or the threat of scleral rupture. Donor sclera, lamellar corneal tissue or fascia lata⁵¹ is suitable in such patients.

3. Cataract Surgery

Cataract formation has been reported at an incidence of 17% in eyes with scleritis in a group of patients followed up over a period of 11 years.¹⁰⁷ Cataract usually develops some time after the onset of scleritis and is related to both the scleritis and corticosteroid therapy. Cataract surgery is safe in these patients, providing the inflammation is quiescent and has been in remission for at least 3 months. Corneal approach phacoemulsification seems the logical technique for cataract surgery as it avoids the sclera and preserves the conjunctiva and its vascular plexuses.

4. Glaucoma Surgery

The incidence of glaucoma over an 11-year period has been reported as high as 13% in patients with scleritis.¹⁰⁷ Elevated intraocular pressure and glaucoma in patients with scleritis needs careful evaluation to determine the mechanism producing the elevated pressure. Angle-closure glaucoma is typically the result of ciliary body rotation rather than pupil block and therefore will not respond to peripheral iridotomy. Chronic angle closure may result in widespread peripheral anterior synechiae and permanent angle closure requiring surgical intervention.

Patients with severe scleritis can develop significant trabecular damage and subsequent open-angle glaucoma that requires surgery for pressure control. Trabeculectomy is the best initial surgical procedure, but

may be technically difficult or impossible due to scleral thinning and those patients require a tube drainage procedure. Anti-metabolites may be needed in high-risk patients and specialist advice should be taken as to the choice of agent.

X. Outcome

The aims of treatment are to control inflammation, eliminate pain, and reduce the occurrences of complications and also to treat any associated systemic disease. It is also important to adequately treat scleritis patients because systemic disease in this group has an associated increased mortality in patients presenting with scleritis.^{2,30} Loss of vision is much more common in eyes with posterior scleritis and has been noted in 30% of patients who in one study lost 2 or more lines of Snellen acuity despite optimal treatment.⁷⁰ Most patients with posterior scleritis who lose vision have secondary macular changes or optic atrophy.⁷⁰ Those with severe disease often have multiple causes for visual loss, such as retinal pigment epithelium changes at the macula, or epiretinal membrane formation, macular edema, cataract, and/or retinal detachment. The presence of peripheral keratopathy in eyes with scleritis is also associated with a poor ocular and systemic prognosis. It is reported that early treatment controlled posterior scleral inflammation and limited visual loss.²

XI. Conclusion

Scleritis is an ocular disease that may be difficult to diagnose and manage. However, with informed and adequate care the long-term prognosis can be excellent both for the patient and the eye and every attempt should be made to achieve this with careful clinical history taking, detailed ocular examination, and the use of immunosuppressant drugs when necessary.

Method of Literature Search

This article was prepared using the National Library of Medicine database 1975–2004 using the following search words: *scleritis* or *ocular* or *eye* or *episcleritis* or *scleral*, and one of the following: *necrotizing*, *systemic*, *immunosuppression*, *infectious*, *sclerokeratitis*, *corneoscleritis*, *acanthamoeba*, *zoster*, *varicella*, *Borrelia*, *leprosy*, *mycobacterium*, *aspergillus*, *buckle*, *polyarteritis nodosa*, *sarcoidosis*, *anticytoplasmic*, *vasculitic*, *granulomatosis*, *rheumatic*, *arthritis*, *scleromalacia*, *transplantation*, *surgery*, *metastatic*, *carcinoma*, *tumour*, *malignant*, *beta irradiation*, *pterygium*, *necrosis*.

Additional sources included textbooks such as those referenced below. Manual searches based upon articles cited in the texts of other articles. Only those

articles in peer-reviewed journals were included. In the case of non-English articles, abstracts were used wherever possible.

References

1. Afshari NA, Afshari MA, Foster CS: Inflammatory conditions of the eye associated with rheumatic diseases. *Curr Rheumatol Rep* 3:453–8, 2001
2. Akova YA, Jabbur NS, Foster CS: Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy. *Ophthalmology* 100:1775–81, 1993
3. Bambery P, Gupta A, Sakhuja V, et al: Ocular manifestations of Wegener's granulomatosis in north India. *Sarcoidosis* 5:132–5, 1988
4. Benson WE: Posterior scleritis. *Surv Ophthalmol* 32:297–316, 1988
5. Bernauer W: Infectious scleritis and surgically induced scleritis, in McCluskey P (ed): *Scleritis*. London: BMJ Books, 2001
6. Bernauer W: [Vision disorders in inflammatory-rheumatic diseases]. *Ther Umsch* 53:58–67, 1996
7. Bernauer W, Allan BD, Dart JK: Successful management of *Aspergillus* scleritis by medical and surgical treatment. *Eye* 12(Pt 2):311–6, 1998
8. Bernauer W, Büchi E.R, Daicker B: Immunopathological findings in posterior scleritis. *Int Ophthalmol* 18:229–31, 1994
9. Bernauer W, Watson PG, Daicker B, et al: Cells perpetuating the inflammatory response in scleritis. *Br J Ophthalmol* 78:381–5, 1994
10. Bhagat S, Ramaesh K, Wharton SB, et al: Spontaneous acute scleritis and scleral necrosis in choroidal malignant melanoma. *Eye* 13(Pt 6):793–5, 1999
11. Bialasiewicz AA: [Eye manifestations of Lyme borreliosis]. *Ophthalmologie* 89:W47–59, 1992
12. Bouza E, Merino P, Muñoz P, et al: Ocular tuberculosis. A prospective study in a general hospital. *Medicine (Baltimore)* 76:53–61, 1997
13. Brod RD, Saul RF: Nodular posterior scleritis. *Arch Ophthalmol* 108:1170–1, 1990
14. Brooks JG, Mills RA, Coster DJ: Nocardial scleritis. *Am J Ophthalmol* 114:371–2, 1992
15. Brunette I, Stulting RD: *Sporothrix schenckii* scleritis. *Am J Ophthalmol* 114:370–1, 1992
16. Cakiner T, Karaçorlu MA: Ophthalmic findings of newly diagnosed leprosy patients in Istanbul Leprosy Hospital, Turkey. *Acta Ophthalmol Scand* 76:100–2, 1998
17. Calthorpe CM, Watson PG, McCartney AC: Posterior scleritis: a clinical and histological survey. *Eye* 2:267–77, 1988
18. Caronia R, Liebmann J, Speaker M, et al: *Corynebacterium* scleritis. *Am J Ophthalmol* 117:405–6, 1994
19. Casey R, Flowers CW, Jones DD, et al: Anterior nodular scleritis secondary to syphilis. *Arch Ophthalmol* 114:1015–6, 1996
20. Charles SJ, Meyer PA, Watson PG: Diagnosis and management of systemic Wegener's granulomatosis presenting with anterior ocular inflammatory disease. *Br J Ophthalmol* 75:201–7, 1991
21. Choudhry S, Rao SK, Biswas J, et al: Necrotizing nocardial scleritis with intraocular extension: a case report. *Cornea* 19:246–8, 2000
22. Dana MR, Hochman MA, Viana MA, et al: Ocular manifestations of leprosy in a noninstitutionalized community in the United States. *Arch Ophthalmol* 112:626–9, 1994
23. Di Girolamo N, Lloyd A, McCluskey P, et al: Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. *Am J Pathol* 150:653–66, 1997
24. Di Girolamo N, Visvanathan K, Lloyd A, et al: Expression of TNF-alpha by human plasma cells in chronic inflammation. *J Leukoc Biol* 61:667–78, 1997
25. Dorey SE, Clark BJ, Christopoulos VA, et al: Orbital lymphoma misdiagnosed as scleritis. *Ophthalmology* 109:2347–50, 2002
26. Dougherty PJ, Binder PS, Mondino BJ, et al: *Acanthamoeba* sclerokeratitis. *Am J Ophthalmol* 117:475–9, 1994
27. Enzenauer RW, Enzenauer RJ, Reddy VB, et al: Treatment of scleromalacia perforans with dura mater grafting. *Ophthalmic Surg* 23:829–32, 1992
28. Finger PT, Perry HD, Packer S, et al: Posterior scleritis as an intraocular tumour. *Br J Ophthalmol* 74:121–2, 1990
29. Fong LP, Sainz de la Maza M, Rice BA, et al: Immunopathology of scleritis. *Ophthalmology* 98:472–9, 1991
30. Foster CS, Forstot SL, Wilson LA: Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. *Ophthalmology* 91:1253–63, 1984
31. Fraunfelder FW, Fraunfelder B: Scleritis and other ocular side effects associated with pamidronate disodium. *Am J Ophthalmol* 135:219–22, 2003
32. Furukawa H, Hamada T, Nagaya K, et al: [A case of necrotizing scleritis associated with Epstein-Barr virus infection]. *Nippon Ganka Gakkai Zasshi* 97:1337–42, 1993
33. Garner A: Pathogenesis of acanthamoebic keratitis: hypothesis based on a histological analysis of 30 cases. *Br J Ophthalmol* 77:366–70, 1993
34. Godkin AJ, Dinning WJ, Anderson MG: Scleritis associated with coxsackie B type 5 infection. *Eye* 8:357–8, 1994
35. Hakin KN, Ham J, Lightman SL: Use of cyclosporin in the management of steroid dependent non-necrotizing scleritis. *Br J Ophthalmol* 75:340–1, 1991
36. Hakin KN, Watson PG: Systemic associations of scleritis. *Int Ophthalmol Clin* 31:111–29, 1991
37. Hall AJ, Barton K, Watson PG, et al: Scleritis in association with poststreptococcal vasculitis. *Arch Ophthalmol* 111:1324–5, 1993
38. Harper SL, Letko E, Samson CM, et al: Wegener's granulomatosis: the relationship between ocular and systemic disease. *J Rheumatol* 28:1025–32, 2001
39. Heiligenhaus A, Michel D, Koch JM: Nodular scleritis in a patient with sarcoidosis. *Br J Ophthalmol* 87:507–8, 2003
40. Helm CJ, Holland GN, Webster RG, et al: Combination intravenous ceftazidime and aminoglycosides in the treatment of pseudomonal scleritis. *Ophthalmology* 104:838–43, 1997
41. Huang FC, Huang SP, Tseng SH: Management of infectious scleritis after pterygium excision. *Cornea* 19:34–v9, 2000
42. Hunyor AP, Harper CA, O'Day J, et al: Ocular-central nervous system lymphoma mimicking posterior scleritis with exudative retinal detachment. *Ophthalmology* 107:1955–9, 2000
43. Hwang YS, Chen YF, Lai CC, et al: Infectious scleritis after use of immunomodulators. *Arch Ophthalmol* 120:1093–4, 2002
44. Illingworth CD, Cook SD: *Acanthamoeba* keratitis. *Surv Ophthalmol* 42:493–508, 1998
45. Jabs DA, Mudun A, Dunn JP, et al: Episcleritis and scleritis: clinical features and treatment results. *Am J Ophthalmol* 130:469–76, 2000
46. Jager MJ, Chodosh J, Huang AJ, et al: *Aspergillus niger* as an unusual cause of scleritis and endophthalmitis. *Br J Ophthalmol* 78:584–6, 1994
47. Jain R, Ionides A, Pavesio C, et al: Scleritis as a presenting feature of Takayasu's disease. *Br J Ophthalmol* 84:801, 2000
48. Jayson MI, Jones DE: Scleritis and rheumatoid arthritis. *Ann Rheum Dis* 30:343–7, 1971
49. Joysey VC, Roger JH, Ashworth F, et al: Parallel studies of HLA antigens in patients with rheumatic heart disease and scleritis: comparisons with three control populations. *J Rheumatol* 3(Suppl):84–8, 1977
50. Kachmaryk M, Bouchard CS, Duffner LA: Bilateral fascia lata patch grafts in a patient with progressive scleromalacia perforans. *Ophthalmic Surg Lasers* 27:397–400, 1996
51. Kachmaryk M, Bouchard CS, Duffner LA: Bilateral fascia lata patch grafts in a patient with progressive scleromalacia perforans. *Ophthalmic Surg Lasers* 27:397–400, 1996

52. Kalina PH, Garrity JA, Herman DC, et al: Role of testing for anticytoplasmic autoantibodies in the differential diagnosis of scleritis and orbital pseudotumor. *Mayo Clin Proc* 65:1110–7, 1990
53. Karia N, Doran J, Watson SL, et al: Surgically induced necrotizing scleritis in a patient with ankylosing spondylitis. *J Cataract Refract Surg* 25:597–600, 1999
54. Kim RY, Anderlini P, Naderi AA, et al: Scleritis as the initial clinical manifestation of graft-versus-host disease after allogeneic bone marrow transplantation. *Am J Ophthalmol* 133:843–5, 2002
55. Kim RY, Seiff SR, Howes EL, et al: Necrotizing scleritis secondary to conjunctival squamous cell carcinoma in acquired immunodeficiency syndrome. *Am J Ophthalmol* 109:231–3, 1990
56. Knox CM, Whitcher JP, Cevallos V, et al: Nocardia scleritis. *Am J Ophthalmol* 123:713–4, 1997
57. Kouida N, Sasaki H, Harada S, et al: Early manifestation of Vogt-Koyanagi-Harada disease as unilateral posterior scleritis. *Jpn J Ophthalmol* 46:590–3, 2002
58. Krist D, Wenkel H: Posterior scleritis associated with *Borrelia burgdorferi* (Lyme disease) infection. *Ophthalmology* 109:143–5, 2002
59. Kumar B, Crawford GJ, Morlet GC: *Scedosporium prolificans* corneal scleritis: a successful outcome. *Aust NZ J Ophthalmol* 25:169–71, 1997
60. Lachmann SM, Hazleman BL, Watson PG: Scleritis and associated disease. *Br Med J* 1:88–90, 1978
61. Langford CA: Wegener's granulomatosis: current and upcoming therapies. *Arthritis Res Ther* 5:180–91, 2003
62. Langford CA, Talar-Williams C, Sneller MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. *Arthritis Rheum* 51:278–83, 2004
63. Larkin G, Lightman S: Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. *Ophthalmology* 106:370–4, 1999
64. Leahey AB, Gottsch JD, Stark WJ: Clinical experience with N-butyl cyanoacrylate (Nexacryl) tissue adhesive. *Ophthalmology* 100:173–80, 1993
65. Lee GA, Gray TB, Dart JK, et al: Acanthamoeba sclerokeratitis: treatment with systemic immunosuppression. *Ophthalmology* 109:1178–82, 2002
66. Lindenmuth KA, Sugar A, Kincaid MC, et al: Invasive squamous cell carcinoma of the conjunctiva presenting as necrotizing scleritis with scleral perforation and uveal prolapse. *Surv Ophthalmol* 33:50–4, 1988
67. Livir-Rallatos C, El-Shabrawi Y, Zafirakis P, et al: Recurrent nodular scleritis associated with varicella zoster virus. *Am J Ophthalmol* 126:594–7, 1998
68. Lyne AJ, Pitkeathley DA: Episcleritis and scleritis. Association with connective tissue disease. *Arch Ophthalmol* 80:171–6, 1968
69. MacKenzie FD, Hirst LW, Kynaston B, et al: Recurrence rate and complications after beta irradiation for pterygia. *Ophthalmology* 98:1776–80; discussion 1781, 1991
70. Mader TH, Stulting RD, Crosswell HH: Bilateral paralimbal scleromalacia perforans. *Am J Ophthalmol* 109:233–4, 1990
71. Mahmood MA, Al-Rajhi A, Riley F, et al: Sclerokeratitis: an unusual presentation of squamous cell carcinoma of the conjunctiva. *Ophthalmology* 108:553–8, 2001
72. Makins R, Ballinger A: Gastrointestinal side effects of drugs. *Expert Opin Drug Saf* 2:421–9, 2003
73. Margo CE, Pavan PR: *Mycobacterium chelonae* conjunctivitis and scleritis following vitrectomy. *Arch Ophthalmol* 118:1125–8, 2000
74. Marsh RJ, Cooper M: Ophthalmic herpes zoster. *Eye* 7:350–70, 1993
75. McCluskey P, Wakefield D: Current concepts in the management of scleritis. *Aust NZ J Ophthalmol* 16:169–76, 1988
76. McCluskey P, Wakefield D: Intravenous pulse methylprednisolone in scleritis. *Arch Ophthalmol* 105:793–7, 1987
77. McCluskey PJ, Watson PG, Lightman S, et al: Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. *Ophthalmology* 106:2380–6, 1999
78. McGavin DD, Williamson J, Forrester JV, et al: Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis. *Br J Ophthalmol* 60:192–226, 1976
79. Messmer EM, Foster CS: Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. *Cornea* 14:408–17, 1995
80. Moriarty AP, Crawford GJ, McAllister IL, et al: Fungal corneal scleritis complicating beta-irradiation-induced scleral necrosis following pterygium excision. *Eye* 7(Pt 4):525–8, 1993
81. Moriarty AP, Crawford GJ, McAllister IL, et al: Bilateral streptococcal corneal scleritis complicating beta irradiation induced scleral necrosis. *Br J Ophthalmol* 77:251–2, 1993
82. Moriarty AP, Crawford GJ, McAllister IL, et al: Severe corneal scleral infection. A complication of beta irradiation scleral necrosis following pterygium excision. *Arch Ophthalmol* 111:947–51, 1993
83. Moshari A, Cheeseman EW, McLean IW: Totally necrotic choroidal and ciliary body melanomas: associations with prognosis, episcleritis, and scleritis. *Am J Ophthalmol* 131:232–6, 2001
84. Nanda M, Pflugfelder SC, Holland S: Fulminant pseudomonal keratitis and scleritis in human immunodeficiency virus-infected patients. *Arch Ophthalmol* 109:503–5, 1991
85. Nanda M, Pflugfelder SC, Holland S: *Mycobacterium tuberculosis* scleritis. *Am J Ophthalmol* 108:736–7, 1989
86. Naseri A, Good WV, Cunningham ET: Herpes zoster virus sclerokeratitis and anterior uveitis in a child following varicella vaccination. *Am J Ophthalmol* 135:415–7, 2003
87. Nguyen QD, Foster CS: Scleral patch graft in the management of necrotizing scleritis. *Int Ophthalmol Clin* 39:109–31, 1999
88. O'Donoghue E, Lightman S, Tuft S, et al: Surgically induced necrotizing sclerokeratitis (SINS)—precipitating factors and response to treatment. *Br J Ophthalmol* 76:17–21, 1992
89. Ormerod LD, Puklin JE, McHenry JG, et al: Scleral flap necrosis and infectious endophthalmitis after cataract surgery with a scleral tunnel incision. *Ophthalmology* 100:159–63, 1993
90. Perlstein SH, Yablonski ME: Spontaneous remission of glaucoma in scleromalacia perforans: a case report. *Ann Ophthalmol* 16:229–30, 1984
91. Pitkeathly DA, Howitt G, Lyne AJ: Scleritis and aortic incompetence. Two manifestations of connective tissue disease. *Ann Rheum Dis* 29:477–82, 1970
92. Polaczek-Kornecka A, Mirkiewicz-Sieradzka B, Heitzman J, et al: [Scleritis resembling choroidal melanoma: a case report]. *Klin Oczna* 101:135–7, 1999
93. Poon A, MacLean H, McKelvie P: Recurrent scleritis in lepromatous leprosy. *Aust NZ J Ophthalmol* 26:51–5, 1998
94. Pope J, Sternberg P, McLane NJ, et al: *Mycobacterium chelonae* scleral abscess after removal of a scleral buckle. *Am J Ophthalmol* 107:557–8, 1989
95. Preoteasa D: [Tuberculous sclerokeratitis and cutaneous tuberculids]. *Oftalmologia* 37:215–20, 1993
96. Quinlan MP, Hitchings RA: Angle-closure glaucoma secondary to posterior scleritis. *Br J Ophthalmol* 62:330–5, 1978
97. Radford R, Brahma A, Armstrong M, et al: Severe sclerokeratitis due to *Pseudomonas aeruginosa* in noncontact-lens wearers. *Eye* 14(Pt 1):3–7, 2000
98. Reynolds MG, Alfonso E: Treatment of infectious scleritis and keratoscleritis. *Am J Ophthalmol* 112:543–7, 1991
99. Riono WP, Hidayat AA, Rao NA: Scleritis: a clinicopathologic study of 55 cases. *Ophthalmology* 106:1328–33, 1999
100. Rodriguez-Ares MT, De Rojas Silva MV, Pereiro M, et al: *Aspergillus fumigatus* scleritis. *Acta Ophthalmol Scand* 73:467–9, 1995
101. Sainz de la Maza M, Foster CS: Necrotizing scleritis after ocular surgery. A clinicopathologic study. *Ophthalmology* 98:1720–6, 1991
102. Sainz de la Maza M, Foster CS, Jabbur NS: Scleritis-associated uveitis. *Ophthalmology* 104:58–63, 1997

103. Sainz de la Maza M, Foster CS, Jabbur NS: Scleritis associated with systemic vasculitic diseases. *Ophthalmology* 102:687–92, 1995
104. Sainz de la Maza M, Foster CS, Jabbur NS: Scleritis associated with rheumatoid arthritis and with other systemic immune-mediated diseases. *Ophthalmology* 101:1281–6; discussion 1287–8, 1994
105. Sainz de la Maza M, Foster CS, Jabbur NS, et al: Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy. *Arch Ophthalmol* 120:15–9, 2002
106. Sainz de la Maza M, Hemady RK, Foster CS: Infectious scleritis: report of four cases. *Doc Ophthalmol* 83:33–41, 1993
107. Sainz de la Maza M, Jabbur NS, Foster CS: Severity of scleritis and episcleritis. *Ophthalmology* 101:389–96, 1994
108. Schuman JS, Weinberg RS, Ferry AP, et al: Toxoplasmic scleritis. *Ophthalmology* 95:1399–403, 1988
109. Scott JA, Clearkin LG: Surgically induced diffuse scleritis following cataract surgery. *Eye* 8(Pt 3):292–7, 1994
110. Sen HN, Suhler EB, Al-Khatib SQ, et al: Mycophenolate mofetil for the treatment of scleritis. *Ophthalmology* 110:1750–5, 2003
111. Shah P, Luqmani RA, Murray PI, et al: Posterior scleritis—an unusual manifestation of Cogan’s syndrome. *Br J Rheumatol* 33:774–5, 1994
112. Shah SS, Lowder CY, Schmitt MA, et al: Low-dose methotrexate therapy for ocular inflammatory disease. *Ophthalmology* 99:1419–23, 1992
113. Sharma A, Kaur R, Kumar S, et al: Fibrin glue versus N-butyl-2-cyanoacrylate in corneal perforations. *Ophthalmology* 110:291–8, 2003
114. Smith JR, Cunningham ET: Atypical presentations of ocular toxoplasmosis. *Curr Opin Ophthalmol* 13:387–92, 2002
115. Smith JR, Levinson RD, Holland GN, et al: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. *Arthritis Rheum* 45:252–7, 2001
116. Snell R, Lemp M: Clinical anatomy of the eye. Malden, Blackwell Scientific Publications, 1989, pp 125–6
117. Sridhar MS, Cohen EJ, Rapuano CJ, et al: *Nocardia asteroides* sclerokeratitis in a contact lens wearer. *CLAO J* 28:66–8, 2002
118. Sykes SO, Riemann C, Santos CI, et al: Haemophilus influenzae associated scleritis. *Br J Ophthalmol* 83:410–3, 1999
119. Tanemoto K, Ishikawa H, Kigasawa K, et al: [Detection of mycobacterial DNA with polymerase chain reaction in eye discharge and gastric juices in a case of scleritis]. *Nippon Ganka Gakkai Zasshi* 101:97–101, 1997
120. Thurairajan G, Hope-Ross MW, Situnayake RD, et al: Polyarthropathy, orbital myositis and posterior scleritis: an unusual adverse reaction to influenza vaccine. *Br J Rheumatol* 36:120–3, 1997
121. Tuft SJ, Watson PG: Progression of scleral disease. *Ophthalmology* 98:467–71, 1991
122. Vanathi M, Sharma N, Titiyal JS, et al: Tectonic grafts for corneal thinning and perforations. *Cornea* 21:792–7, 2002
123. Veenashree MP, Sangwan VS, Vemuganti GK, et al: Acute scleritis as a manifestation of congenital erythropoietic porphyria. *Cornea* 21:530–1, 2002
124. Wakefield D, McCluskey P: Cyclosporin therapy for severe scleritis. *Br J Ophthalmol* 73:743–6, 1989
125. Walton RC, Reed KL: Herpes zoster ophthalmicus following bone marrow transplantation in children. *Bone Marrow Transplant* 23:1317–20, 1999
126. Watanabe K, Kato T, Hayasaka S: Concurrent bilateral posterior scleritis and Vogt-Koyanagi-Harada disease in a patient with positive rheumatoid factor. *Ophthalmologica* 211:316–9, 1997
127. Watson PG, Bovey E: Anterior segment fluorescein angiography in the diagnosis of scleral inflammation. *Ophthalmology* 92:1–11, 1985
128. Watson PG, Hazleman BL: The sclera in systemic disorders. London, Philadelphia: W.B. Saunders and Co. Ltd, 1976
129. Watson PG, Lobascher D: The diagnosis and management of episcleritis and scleritis. *Trans Ophthalmol Soc UK* 85:369–78, 1965
130. Wilhelmus KR, Grierson I, Watson PG: Histopathologic and clinical associations of scleritis and glaucoma. *Am J Ophthalmol* 91:697–705, 1981
131. Womack LW, Liesegang TJ: Complications of herpes zoster ophthalmicus. *Arch Ophthalmol* 101:42–5, 1983
132. Yap EY, Robertson DM, Buettner H: Scleritis as an initial manifestation of choroidal malignant melanoma. *Ophthalmology* 99:1693–7, 1992
133. Yeo JH, Jakobiec FA, Iwamoto T, et al: Metastatic carcinoma masquerading as scleritis. *Ophthalmology* 90:184–94, 1983
134. Younan N, McClellan K: Squamous cell carcinoma with necrotizing scleritis. *Aust NZ J Ophthalmol* 27:149–51, 1999
135. Zamir E, Read RW, Smith RE, et al: A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis. *Ophthalmology* 109:798–805; discussion 805–7, 2002

The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

Reprint address: Professor Susan Lightman, Department of Clinical Ophthalmology, Moorfields Eye Hospital, City Road, London EC1V 2PD, UK.